Director/PDMR Shareholding

RNS Number : 2304I

Arix Bioscience Plc

01 December 2022

 

Arix Bioscience plc
("Company")

PDMR notification & Director Shareholding

The Company announces the annual award of nil cost options to CEO Robert Lyne, which are subject to performance conditions over a three-year assessment period from 1 January 2022 to 31 December 2024 in accordance with the Company's Executive Incentive Plan ("EIP") as disclosed in the Company's Remuneration Policy ("Policy"). Vested Shares are subject to a further two year holding period, as set out in the Policy.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Robert Lyne
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Arix Bioscience plc
b)	LEI	213800OVT3AHQCXNIX43
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Arix Bioscience plc Ordinary shares of 0.001 pence each
	Identification code	GB00BD045071
b)	Nature of the transaction	Award of nil-cost options under the Arix Bioscience plc Executive Incentive Plan ("EIP")
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			Nil	636,792
d)	Aggregated information
	- Aggregated volume	N/A (Single Transaction)
	- Price	N/A (Single Transaction)
e)	Date of the transaction	30 November 2022
f)	Place of the transaction	Outside a trading venue

For further information please contact:
Kin Company Secretarial Limited, Company Secretary
[phone]

 

END

 

 

DSHDFLBBLLLXFBQ